COVID-19 patients carry particularly high viral loads during the early stages of the disease, with millions of virus exhaled in their breath per hour, reveals a study — which indicates that breath emission could possibly contribute to airborne transmission of the virus.
A 4-week delay in cancer treatment can increase mortality across surgical, systemic treatment, and radiotherapy indications for seven cancers, with longer delays being more and more harmful to patients, suggest the results of a systematic review and meta-analysis.
Giving crushed prasugrel to patients with ST-segment elevation myocardial infarction (STEMI) en route to the hospital for planned PCI* does not improve reperfusion rates compared with giving the tablets whole in the COMPARE CRUSH trial.
Meteorological factors, such as humidity, precipitation, ambient temperature, and wind speed, seem to affect the transmissibility of the respiratory syncytial virus (RSV), according to a recent Singapore study.
Men with nonmetastatic castration-resistant prostate cancer (nmCRPC) who have rapidly rising levels of prostate-specific antigen (PSA) see radiographic progression of their malignancy even without meeting the criteria set by the Prostate Cancer Working Group 2 (PCWG2), a recent study has shown.
New drug applications approved by US FDA as of 16 - 30 November 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
An evidence-based, multifaceted intervention aimed at reducing haemodialysis catheter-related bloodstream infections (HD-CRBSIs) failed to improve this outcome, results of the REDUCCTION* trial showed.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.